Literature DB >> 33823460

An ethical dimension to accident management and health surveillance.

Deborah Oughton1, Liudmila Liutsko2, Sanae Midorikawa3, Philippe Pirard4, Thierry Schneider5, Yevgeniya Tomkiv6.   

Abstract

Many radiation protection actions carry a multitude of direct and indirect consequences that can impact on the welfare of affected populations. Health surveillance raises ethical challenges linked to privacy and data protection, as well as questions about the net benefit of screening. The SHAMISEN project recognized these issues and developed specific recommendations to highlight ethical challenges. Following a brief overview of ethical issues related to accident management, this paper presents the SHAMISEN recommendations: R1 The fundamental ethical principle of doing more good than harm should be central to accident management; and R4 Ensure that health surveillance respects the autonomy and dignity of affected populations, and is sensitive to any inequity in the distribution of risks and impacts. While a holistic approach to accident management means that decisions will be complicated by different values, perceptions and uncertainties about outcomes, addressing ethical issues could help ensure that the assumptions and potential conflicts behind eventual decisions are as transparent as possible.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Keywords:  Autonomy; Equity; Ethics; Health surveillance; Justice; Nuclear accidents

Year:  2021        PMID: 33823460     DOI: 10.1016/j.envint.2021.106537

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  1 in total

1.  Young people's perspectives of thyroid cancer screening and its harms after the nuclear accident in Fukushima Prefecture: a questionnaire survey indicating opt-out screening strategy of the thyroid examination as an ethical issue.

Authors:  Sanae Midorikawa; Akira Ohtsuru
Journal:  BMC Cancer       Date:  2022-03-03       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.